Discover
ATNM
Actinium Pharmaceuticals, Inc.
0.98
400 x undefined
300 x undefined
bid
ask
-
0.00
0.02%
350 @ 04:00 PM
1.00 +0.02 (1.91%)
| Ytd | -27.96% | |
| 1y | -27.42% |
0.97
day range
0.99
0.94
52 week range
1.89
| Open | 0.97 | Prev Close | 0.98 | Low | 0.97 | High | 0.99 | Mkt Cap | 30.74M |
| Vol | 90.78K | Avg Vol | 180.83K | EPS | -0.76 | P/E | N/A | Forward P/E | -1.77 |
| Beta | 0.15 | Short Ratio | 5.72 | Inst. Own | 30.11% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-08 | 50-d Avg | 1.15 | 200-d Avg | 1.29 | 1yr Est | 5.00 |
ATNM News
benzinga.com
Actinium's ATNM-400 Reports Preclinical Activity And Combination Synergy Across KRAS- And EGFR-Mutan
New KRAS-mutant data show ATNM-400 outperformed standard-of-care inhibitors sotorasib and adagrasib
benzinga.com
Actinium Pharma Presents New Data On ATNM-400 In Prostate Cancer At SNMMI 2026 Annual Meeting
New data demonstrated ATNM-400 remains potently active in prostate cancer cells and tumors resistant